A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

What Was Tested

This registered phase 3 trial tested Orforglipron (Foundayo, non-peptide).

GZL2 is an independent study conducted under the GZPL master protocol.

It had two arms (groups): Orforglipron (experimental) and Placebo (placebo comparator).

Participants will receive orforglipron orally.

Participants receive placebo.

The registry classes the interventions as drug.

Who Took Part

Enrollment: 487 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Refer to the GZPL master protocol study for screening eligibility.

The full record lists 1 inclusion and 1 exclusion criteria; among the exclusions: refer to the gzpl master protocol study for screening eligibility.

How the Study Was Run

Design: randomized, parallel-group and double-blind.

Random assignment meant chance, not the researchers, decided who got Orforglipron (Foundayo, non-peptide) and who got the comparison, which limits bias.

The Orforglipron (Foundayo, non-peptide) group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on Orforglipron (Foundayo, non-peptide), so expectations could not easily colour the readings.

Those kept unaware of assignments: participant and investigator.

It started in 2025-04-30 with completion listed for 2027-09.

It ran at 99 sites in United States (28), China (12), Argentina (9), Czechia (9), Germany (9) and Poland (8).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Change from Baseline in office Systolic Blood Pressure (SBP) (time frame: Baseline to Week 36).

It also tracked 7 secondary outcomes, for example Change from Baseline in 24-hour Ambulatory Blood Pressure Monitoring (ABPM) SBP, Percent Change from Baseline in Body Weight, Percent Change from Baseline in Lipids Triglycerides, Percent Change from Baseline in Lipids non-HDL Cholesterol, Percent Change from Baseline in hsCRP Concentration (mg/L) and Percent Change from Baseline in office SBP in Randomized Withdrawal Population.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Orforglipron (Foundayo, non-peptide) in 487 people.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Orforglipron (Foundayo, non-peptide) compound page, all human trials.